2023-07-07 07:00:00
US green light for Pfizer
The FDA has just approved the Go up (somatrogon-ghla) from the world’s number one human growth hormone analogue for children over the age of three with endogenous growth hormone deficiency. Administered once a week, this drug should make it possible to reduce the frequency of injection, often daily. Ngenla is expected to be available for prescription in the United States, beginning in August 2023.
Janssen makes progress once morest psoriasis
At branches of NOT A WORD communicated the phase IIb results of the JNJ-2113, an interleukin-23 receptor antagonist being evaluated in adults for moderate to severe plaque psoriasis. The peptide met all primary and secondary endpoints. Janssen is already preparing to launch phase III. About eight million Americans and more than 125 million people worldwide live with this condition.
Moderna Files Claims Against VRS
The biotech has submitted applications for authorization for its vaccine candidate mRNA-1345 once morest respiratory syncytial virus (RSV) with various agencies, including the EMA, that of Switzerland and that of Australia. In phase III, the compound achieved 83.7% efficacy once morest respiratory infections due to RSV in people over the age of 60. Recently, GSK was granted an authorization in this indication.
Selected for you
1688725863
#pipelines #Pfizer #Janssen #Moderna
